Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Sagimet Biosciences Inc.NASDAQ: SGMT
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 26.8% from a year ago
Other current assets stood at $650K at the end of Q1 FY2026, down 26.8% from a year earlier and up 35.1% from the prior quarter. Over 3 fiscal years it compounded at +141.9% a year.
Context
- Other current assets amounted to 0.6% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -26.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 481K USD
- Year-over-year change
- +3.9%
- 4-year CAGR
- -24.9%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 481K | +3.9% |
| FY2024 | 2024-12-31 | 463K | +16.6% |
| FY2023 | 2023-12-31 | 397K | +1067.6% |
| FY2022 | 2022-12-31 | 34K | -97.7% |
| FY2021 | 2021-12-31 | 1.51M | — |
Other Current Assets vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 other current assets of $650K is the lowest of the 11 companies compared; the peer median is $4.43M.
- Its year-over-year change of -26.8% is the 7th highest of 11, against a peer median of -5.5%.
- Other current assets amounts to 0.6% of total assets for SGMT, versus a peer median of 2.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $161.25B | +6889679.5% | +2.1% | 75.1% | |
| Mar 2026 | $9.73M | -47.8% | -27.8% | 2.9% | |
| Mar 2026 | $7.19M | -13.1% | -13.6% | 2.7% | |
| Mar 2026 | $5.56M | +35.7% | +163.2% | 2.4% | |
| Mar 2026 | $4.7M | +100.2% | +12.5% | 4.3% | |
| Mar 2026 | $4.16M | -89.2% | -17.0% | 1.7% | |
| Mar 2026 | $3.86M | -45.5% | +1.9% | 1.8% | |
| Mar 2026 | $3.18M | -34.1% | -8.1% | 1.4% | |
| Mar 2026 | $1.79M | +2.1% | +11.6% | 5.4% | |
ZURAZura Bio Limited | Mar 2026 | $1.41M | +25.6% | +148.4% | 0.6% |
SGMTSagimet Biosciences Inc. | Mar 2026 | $650K | -26.8% | +141.9% | 0.6% |
| Peer median (excluding SGMT) | $4.43M | -5.5% | +2.0% | 2.5% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.